• Hongjie Yuan, Scott J Myers, Gordon Wells, Katherine L Nicholson, Sharon A Swanger, Polina Lyuboslavsky, Yesim A Tahirovic, David S Menaldino, Thota Ganesh, Lawrence J Wilson, Dennis C Liotta, James P Snyder, and Stephen F Traynelis.
• Department of Pharmacology, Emory University, Atlanta, GA 30322, USA.
• Neuron. 2015 Mar 18;85(6):1305-18.

AbstractStroke remains a significant problem despite decades of work on neuroprotective strategies. NMDA receptor (NMDAR) antagonists are neuroprotective in preclinical models, but have been clinically unsuccessful, in part due to side effects. Here we describe a prototypical GluN2B-selective antagonist with an IC50 value that is 10-fold more potent at acidic pH 6.9 associated with ischemic tissue compared to pH 7.6, a value close to the pH in healthy brain tissue. This should maximize neuroprotection in ischemic tissue while minimizing on-target side effects associated with NMDAR blockade in noninjured brain regions. We have determined the mechanism underlying pH-dependent inhibition and demonstrate the utility of this approach in vivo. We also identify dicarboxylate dimers as a novel proton sensor in proteins. These results provide insight into the molecular basis of pH-dependent neuroprotective NMDAR block, which could be beneficial in a wide range of neurological insults associated with tissue acidification.Copyright © 2015 Elsevier Inc. All rights reserved.

23 keywords...

hide…